In contrast to large trials of CD19‐directed CAR T‐cell therapy (Table 1), none of our patients showed evidence of neurotoxicity, CRS, haemophagocytic lymphohistiocytosis or GVHD, nor were any admitted to the intensive care unit because of toxicities related to CAR‐NK cell treatment. This evidence concerns the gene CD19 and congenital rubella syndrome.